Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.

This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...

President Donald Trump issued executive orders late Friday reviving some of his first term’s anti-abortion policies, like ...

U.S. President Donald Trump plans to impose tariffs on imported computer chips, pharmaceuticals and steel, he said on Monday, ...

The FDA approved a monthly maintenance dosing of intravenous lecanemab (Leqembi) for early Alzheimer's disease, said ...

The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...

In recent health developments, Akero Therapeutics' drug shows promise for liver disease, Eisai/Biogen's Alzheimer's drug ...

The US Food and Drug Administration (FDA) has approved a new dosing regimen for LEQEMBI, a treatment for early Alzheimer’s disease, according to Eisai and Biogen Inc. The maintenance dosing will now ...

The Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody ...

By Francis Page, Jr. Click here for updates on this story January 28, 2025 (Houston Style Magazine) — Sisters Network® Inc. (SNI), the nation’s only African American breast cancer survivorship ...

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta.